Loading in 2 Seconds...
Loading in 2 Seconds...
Drug Management of Second-line anti-TB drugs through the Green Light Committee mechanism for programmes funded by the Global Fund to Fight Against AIDS, tuberculosis and malaria. Geneva, 13 December, 2005 Fabienne Jouberton Ernesto Jaramillo World Health Organization.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Drug Management of Second-line anti-TB drugs through the Green Light Committee mechanism for programmes funded by the Global Fund to Fight Against AIDS, tuberculosis and malaria
Geneva, 13 December, 2005
World Health Organization
“to help contain resistance to second-lineanti-TB drugs and consistent with the policies of other international funding sources, all procurement of medications to treat MDR-TB must be conducted through the Green Light Committee (GLC)”
Third Board Meeting, 10-11 October, 2002
The Global Fund to Fight AIDS, Tuberculosis and Malaria
“Specific funding for DOTS-Plus and support to purchasing second-line drugs for the management of MDR-TB will be granted upon submission, review, and approval of an application to the GLC.
GFATM will provide a GLC application form to the countries approved for funding by the Board; and will make this form part of the GFTAM form for the next rounds.
“GLC will monitor DOTS-Plus and the use of second-line drugs throughout the entire period of funding by GFATM. If case monitoring visits reveal the (potential) misuse of second line drugs the GLC will communicate the findings to the GFATM and the procurement of preferentially priced drugs may be interrupted”
Assurance of drug quality;
Quantitative assessment of drug requirements;
Management of procurement and distribution;
Ensuring rational drug use.
Drug registration status of products selected
Customs regulations for importing drugs
Drug forecast based on treatment regimen, cohort size and pace of patient enrolment
Shelf-life of the products
Lead time for delivery of the drugs
Estimated size of buffer stock (two to three times the delivery delay)
- Forecasting the needs without taking in consideration all variables presented
Please suggest recommendations on how to use the GF grant to ensure proper drug management of second-line TB drugs